Impedimed Limited · ASX:IPD
Impedimed — Wilson's HTM Investment Group Life Sciences Conference (November 2010)
25 slides from Impedimed's conference presentation, Nov 11, 2010
Slide 1: ASX Release – Shareholder Update Presentation
ASX : IPD For personal use only 11 November, 2010 ASX RELEASE – Shareholder Update Presentation Today, ImpediMed’s Managing Director and Chief Executive Officer, Greg Brown, is presenting a Company update at Wilson’s HTM Investment Group Life Sciences Conference in Sydney. ImpediMed Limited wishes t
Slide 2: ImpediMed Limited November 2010
For personal use only ImpediMed Limited November 2010 1
Slide 3: Disclaimer
Disclaimer For personal use only This presentation has been produced by ImpediMed Limited (“ImpediMed”) only and may contain forward-looking statements that are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual res
Slide 4: Executive Summary
Executive Summary For personal use only Designs, develops and sells medical devices to aid in the clinical assessment of lymphoedema Targeting to build its business on five key pillars 1. Identifying first to market opportunities addressing a large underserved medical need in lymphoedema 2. IP
Slide 5: Targeting Multiple Fluid Status Markets
Targeting Multiple Fluid Status Markets For personal use only Lymphoedema market - Arms Today & Near Term Lymphoedema market - Legs Arms – mainly breast cancer Legs – pelvic cancer Highest awareness 80% of market, 70% unilateral Estimate - US$150m+ annually Estimate -US$400m+ annually Fl
Slide 6: Lymphoedema – Current Diagnosis is Often Too Late
Lymphoedema – Current Diagnosis is Often Too Late For personal use only Presently diagnosed when patients has visible symptoms – at this point patient often has irreversible changes Successful treatment and potential prevention can occur through early detection and intervention 5
Slide 7: ImpediMed's L-Dex U400
ImpediMed’s L-Dex® U400 For personal use only • FDA cleared to aid in clinical assessment of unilateral arm of female breast cancer patient • Unilateral claim only at present 6
Slide 8: Limited Competition Today – monitoring for future potential threats
Limited Competition Today – monitoring for future potential threats For personal use only New Market Entrants Present options limited Possible threat with BIA Increasing hurdles – Code, FDA IP position – hurdle Supplier Power Competitive Rivalry Buyer Power Brand–building collateral in L-D
Slide 9: Business Model – Reimbursement Critical to Drive Model
Business Model – Reimbursement Critical to Drive Model For personal use only Illustrative Device Economics Assumptions (based on primary target surgeon) Per Test Per Annum Target list price per test USD $45 (USD) (USD) Clinician enrols 8 patients per month Reimbursement¹ $100 $115,200 Quarterl
Slide 10: Health Insurance coverage (covered lives) - Targeting Major Payers
Health Insurance coverage (covered lives) - Targeting Major Payers For personal use only Targeting a meeting with key Medical Directors for November 2010 Meetings have taken place & reviewing policies – advanced review Targeting a meeting with key Medical Directors in early 2011 No contact to date –
Slide 11: Stanford BIS Registry – Targeting Medicare Sponsorship
Stanford BIS Registry – Targeting Medicare Sponsorship For personal use only MEDCAC panel meeting – “clinical evidence for the diagnosis & treatment of secondary Medicare Evidence lymphoedema” (November 2009) Development and Key note speaker - Dr Rockson (Stanford) Coverage Advisory Committee (M
Slide 12: Current Device Placements in the US — Limited by Reimbursement
Current Device Placements in the US — Limited by Reimbursement 15+ L-Dex™ Agreements Gg 10-15 L-Dex™ Agreements GQ 5-10 L-Dex™ Agreements ) 1-5 L-Dex™ Agreements (-) NoL-Dex™ Agreements
Slide 13: Announcements/Media since last presentation
Announcements/Media since last presentation For personal use only Announcements 105 L-Dex devices placed in the market – estimated140 surgeons having access BIS the new gold standard 2009 rebuttal – editorial published in November 2010 JOL Komen sponsored standard of care pilot for Dr Schonh
Slide 14: Announcements/Media since last presentation
Announcements/Media since last presentation For personal use only Website updates ImpediMed website Dr Rockson (Stanford) Dr Whitacre (ASBS President) Dr Whitworth (MedScape CME) Dr McGarvey (NIH) videos www.impedimed.com/knowledge-center/physician-resources/ www.L-Dex.com – patient
Slide 15: Lymphoedema in Breast Cancer: Update on Early Detection & Treatment
Lymphoedema in Breast Cancer: Update on Early Detection & Treatment For personal use only Readers YTD: 5,832 http://cme.medscape.com/viewarticle/723452 Posted 6/23/10 Pat W. Whitworth, MD 519 Hem/Onc MDs 2,433 Surgeons 1,435 Other MDs 90 NPs 551 Nurses 190 PAs 30 Pharmacists 58
Slide 16: MedScape – post activity survey
MedScape – post activity survey (qualitative data only) For personal use only Program To Date Stats Physicians Hem/Onc Primary Care Other No. Question & Answ ers Specialists Surgeons Physician Physicians Total 1 How often should she be screened for lymphedema? 1 Tw ice a month for another yea 4.2% 6
Slide 17: MedScape – activity evaluation feedback
MedScape – activity evaluation feedback (qualitative data only) For personal use only Phys icians Hem/Onc Primary Care Other No. Que s tion & Ans w e rs Specialists Surgeons Physician Physicians 3 This activity w ill assist in the improvement of my: [Check all that apply.] 1 Competence 73.5% 64.5% 6
Slide 18: IMS Independent Health Economics – due middle of November
IMS Independent Health Economics – due middle of November For personal use only 17
Slide 19: IMS Independent Health Economics – due middle of November
IMS Independent Health Economics – due middle of November For personal use only 18
Slide 20: On model prior to QC
For personal use only On model prior to QC 19
Slide 21: Some of the hurdles experienced over the last six months
Some of the hurdles experienced over the last six months For personal use only 1. Medical Directors of major Payers Health economic outcomes and clinical benefits needed – economic model should help Interest in pre-emptive care but have little understanding of the limitations of conventional met
Slide 22: Washington Post article Nov 9th 2010
Washington Post article Nov 9th 2010 For personal use only It's the after shock of cancer surgery, a complication that breast cancer survivor Bonnie Pike of Phoenix calls "cancer treatment's dirty little secret," a nasty surprise that sneaks up on you. "My surgeon said he'd never had anybody ever
Slide 23: Incidence rates with conventional methods – wide variations
Incidence rates with conventional methods – wide variations For personal use only 1.“Although incidence is generally accepted at approximately 30%, reported rates vary greatly, ranging between 2% & 83%...Differences in lymphedema measurement technique, definitions of what constitutes lymphedema, & t
Slide 24: Recent Senior Appointments
Recent Senior Appointments For personal use only 1. Peggy Brooker - Chief Financial Officer - extensive experience in public accounting includes publicly traded companies in the financial services, manufacturing, retail and education industries. Peggy was a partner with Ernst & Young in Southern Cal
Slide 25: Estimated News Flow – Next Months
Estimated News Flow – Next 18 Months For personal use only News Flow Pipeline: 2H10 1H11 2H11 Unilateral Leg Filing Announcement of first coverage statement Expansion of sales team and managed care team Publish Category III code in AMA coding book Announcement of 20 million covered lives Registry an
ImpediMed — Wilson's HTM Investment Group Life Sciences Conference (November 2010) on 6ix